Dihydroquercetin treatment can decrease ROS production and NLRP3 inflammasome activation to improve fibrosis in rats with high fat diet (HFD)/streptozotocin-induced diabetic nephropathy (DN) (Ding et al., 2018). Here, NLRP3 is linked to liver dysplastic nodule.